dCBI for Inflammatory Bowel Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Children's Hospital of Pittsburgh, Pittsburgh, PA
Inflammatory Bowel Diseases+1 More
dCBI - Behavioral
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

Evaluate the feasibility and acceptability of adapted coached RxWell for patients ages 16-25. Adapt and beta test the modified RxWell product to include chronic disease management and transition readiness. Evaluate RxWell usage and its impact to the TRAQ questionnaire over time.

Eligible Conditions

  • Inflammatory Bowel Diseases
  • Mental Health Issue

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 6 months

6 months
Change in Transition Readiness to Adult Care
Change in anxiety severity over time
Change in depression severity

Trial Safety

Trial Design

2 Treatment Groups

Digital Cognitive Behavioral Intervention (DCBI)
1 of 2
dCBI
1 of 2
Experimental Treatment

50 Total Participants · 2 Treatment Groups

Primary Treatment: dCBI · No Placebo Group · N/A

Digital Cognitive Behavioral Intervention (DCBI)
Behavioral
Experimental Group · 1 Intervention: dCBI · Intervention Types: Behavioral
dCBI
Behavioral
Experimental Group · 1 Intervention: dCBI · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Children's Hospital of Pittsburgh · Pittsburgh, PA
Photo of Pittsburgh 1Photo of Pittsburgh 2Photo of Pittsburgh 3
2011First Recorded Clinical Trial
6 TrialsResearching Inflammatory Bowel Diseases
216 CompletedClinical Trials

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,595 Previous Clinical Trials
6,284,532 Total Patients Enrolled
12 Trials studying Inflammatory Bowel Diseases
217,173 Patients Enrolled for Inflammatory Bowel Diseases
Sandra Kim, MDPrincipal InvestigatorUniversity of Pittsburgh

Eligibility Criteria

Age < 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a native English speaker.
You have access to a smartphone.
You have a PHQ-4 score ≥ 5 and/or a TRAQ score ≥ 60.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.